Sodium Bicarbonate 8.4% Prefilled Syringes 50 mL
Sodium Bicarbonate 8.4% Prefilled Syringes 50 mL is a sterile, nonpyrogenis, hypertonic solution of sodium bicarbonate (NaHCO3) in water for injection for administration by the intravenous route as an electrolyte replenisher and systemic alkalizer. Solution is offered in 8.4% concentration. The solution has an approximate pH of (7.5 to 8.5). Sodium Bicarbonate solution contains no bacteriostat, antimicobial agent or added buffer and is intended only for use as a single-dose injection. Luer-Jet Luer-Lock Prefilled Syringe used for Intravenous use in Metabolic Acidosis. Popular with OBGYN Practices and lab testing. Buy Sodium Bicarbonate 8.4% Prefilled Syringes 50 mL online from a set aside SDVOSB Service-Disabled Veteran-Owned Small Business today!
Medical Audience: Treatment of metabolic acidosis, Severe renal disease, Uncontrolled diabetes, Circulatory insufficiency due to shock, Serve dehydration, Extracorporeal circulation of blood, Cardiac arrest, and Severe primary lactic acidosis.
Category: Metabolic Acidosis
Medical Conditions: Correction of Metabolic Acidosis and other conditions requiring systemic alkalinization.
Liquid in glass. Handle with care. Inspect vial for damage prior to assembly.
Use Aseptic Technique. Do not assemble until ready to use.
1. Remove caps from vial and injector.
2. Insert vial into injector without exerting excessive force. Ensure that vial and injector are properly aligned. Gently rotate vial clockwise (about 3 turns) until medication enters needle. If resistance is encountered, remove vial and repeat procedure.
3. To access green male luer lock adapter, push yellow hood in and then twist counterclockwise. OR - To access needle, twist and pull yellow hood clockwise to remove hood and green adapter.
4. Apply gentle downward pressure on vial to initiate liquid flow.
Note: Very Important. Do not apply excessive force to vial.
Intravenous sodium bicarbonate therapy increases plasma bicarbonate, buffers excess hydrogen ion concentration, raises blood pH and reverses the clinical manifestations of acidosis.
Sodium bicarbonate in water dissociates to provide sodium (Na+) and bicarbonate (HCO3) ions. Sodium (Na+) is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Bicarbonate (HCO3) is a normal constituent of body fluids and the normal plasma levels ranges from 24 to 31 mEq/liter. Plasma concentration is regulated by the kidney through acidification of urine when there is a deficit or by alkalinization of the urine when there is an excess. Bicarboante anion is considered "labile" since at a proper concentration of hydrogen ion (H+) it may be converted to carbonic acid (H2CO3) and thence to its volatile form, carbon dioxide (CO2) excreted by the lung.
Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention. In patients with diminished renal function, administration of sollutions containing sodium ions may result in sodium retention.
The intravenous administration of these solutions can cause fluid and/o solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states of pulmonary edema. Extravascular infiltration should be avoided.
|Container Type||Prefilled Syringe|
|Generic Drug Code||02752|
|Generic Drug Name||Sodium Bicarbonate, Preservative Free|
|Strength||1 mEq / mL|
Warnings: Solutions containing sodium ions should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists<br />edema with sodium retention. In patients with diminished renal function, administration of solutions containing sodium ions may result in sodium retention. The intravenous administration of these solutions can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states or pulmonary edema. Extravascular infiltration should be avoided, see ADVERSE REACTIONS. Precautions: The potentially large loads of sodium given with bicarbonate require that caution be exercised in the use of sodium bicarbonate in patients with congestive heart failure or other edematous or sodium retaining states, as well as in patients with oliguria or anuria. See table in HOW SUPPLIED section for amounts of sodium present in solutions. Caution must be exercised in the administration of parenteral fluids, especially those containing sodium ions, to patients receiving corticosteroids or corticotropin. Potassium depletion may predispose to metabolic alkalosis and coexistent hypocalcemia may be associated with carpopedal spasm as the plasma pH rises. These dangers can be minimized if such electrolyte imbalances are appropriately treated prior to or concomitantly with bicarbonate infusion. Rapid injection (10 mL/min.) of hypertonic Sodium Bicarbonate Injection, USP, solutions into neonates and children under two years of age may produce hypernatremia, a decrease in cerebrospinal fluid pressure and possible intracranial hemorrhage. The rate of administration in such patients should therefore be limited to no more than 8 mEq/kg/day. A solution diluted to 4.2% may be preferred for such slow administration. In emergencies such as cardiac arrest, the risk of rapid infusion must be weighed against the potential for fatality due to acidosis. Drug Interactions: Additives may be incompatible; norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. The addition of sodium bicarbonate to parenteral solutions containing calcium should be avoided, except where compatibility has been previously established. Precipitation or haze may result from sodium bicarbonate-calcium admixtures. Note: Do not use the injection if it contains precipitate.</p> <p>Additives may be incompatible. Consult with pharmacist, if available. When introducing additives, use aseptic technique, mix throughly and do not store. Laboratory Tests: The aim of all bicarbonate therapy is to produce a substantial correction of the low total CO2 content and blood pH, but the risks of overdosage and alkalosis should be avoided. Hence, repeated fractional doses and periodic monitoring by appropriate laboratory tests are recommended to minimize the possibility of overdosage. Animal reproduction studies have not been conducted with sodium bicarbonate. It is also not known whether sodium bicarbonate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Sodium bicarbonate should be given to a pregnant woman only if clearly needed.
Adverse Reactions: Overly aggressive therapy with Sodium Bicarbonate Injection, USP can result in metabolic alkalosis (associated with muscular twitchings, irritability and tetany) and hypernatremia. Inadvertent extravasation of intravenously administered hypertonic solutions of sodium bicarbonate have been reported to cause chemical cellulitis because of their alkalinity, with tissue necrosis, ulceration or sloughing at the site of infiltration. Prompt elevation of the part, warmth and local injection of lidocaine or hyaluronidase are recommended to prevent sloughing of extravasated IV infusions.Overdosage Should alkalosis result, the bicarbonate should be stopped and the patient managed according to the degree of alkalosis present. 0.9% sodium chloride injection intravenous may be given; potassium chloride also may be indicated if there is hypokalemia. Severe alkalosis may be accompanied by hyperirritability or tetany and these symptoms may be controlled by calcium gluconate. An acidifying agent such as ammonium chloride may also be indicated in severe alkalosis. See WARNINGS and PRECAUTIONS. Dosage and Administration: Sodium Bicarbonate Injection, USP is administered by the intravenous route. In cardiac arrest, a rapid intravenous dose of 200 to 300 mEq of bicarbonate, given as a 7.5% or 8.4% solution is suggested for adults. Cautions should be observed in emergencies where very rapid infusion of large quantities of bicarbonate is indicated. Bicarbonate solutions are hypertonic and may produce an undesirable rise in plasma sodium concentration in the process of correcting the metabolic acidosis. In cardiac arrest, however, the risks from acidosis exceed those of hypernatremia. In infants (up to two years of age), intravenous administration at a dose not to exceed 8 mEq/kg/day is recommended. Slow administration rates and a solution diluted to 4.2% are recommended in neonates, to guard against the possibility of producing hypernatremia, decreasing cerebrospinal fluid pressure and inducing intracranial hemorrhage. In less urgent forms of metabolic acidosis, Sodium Bicarbonate Injection, USP may be added to other intravenous fluids. The amount of bicarbonate to be given to older children and adults over a four-toeight- hour period is approximately 2 to 5 mEq/kg of body weight — depending upon the severity of the acidosis as judged by the lowering of total CO2 content, blood pH and clinical condition of the patient. Bicarbonate therapy should always be planned in a stepwise fashion since the degree of response from a given dose is not precisely predictable. Initially an infusion of 2 to 5 mEq/kg body weight over a period of 4 to 8 hours will produce a measurable improvement in the abnormal acidbase status of the blood. The next step of therapy is dependent upon the clinical response of the patient. If severe symptoms have abated, then the frequency of administration and the size of the dose may be reduced.</p> <p>In general, it is unwise to attempt full correction of a low total CO2 content during the first 24 hours of therapy, since this may be accompanied by an unrecognized alkalosis because of a delay in the readjustment of ventilation to normal. Owing to this lag, the achievement of total CO2 content of about 20 mEq/liter at the end of the first day of therapy will usually be associated with a normal blood pH. Further modification of the acidosis to completely normal values usually occurs in the presence of normal kidney function when and if the cause of the acidosis can be controlled. Values for total CO2 which are brought to normal or above normal within the first day of therapy are very likely to be associated with grossly alkaline values for blood pH, with ensuing undesired side effects. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. See PRECAUTIONS. Do not use unless solution is clear and the container or seal is intact. Discard unused portion.
Brand: Pfizer Injectables
Buy Sodium Bicarbonate 8.4% Prefilled Syringes 50 mL online from a set aside SDVOSB Service-Disabled Veteran-Owned Small Business medical supplies company certified with the United Stated Government on SAM.GOV today.